Fujisawa Pharmaceutical Company, Ltd.

Research Association for Biotechnology

Other

Chugai Seiyaku Kabushiki Kaisha

Reverse Proteomics Research Institute Co., Ltd.

Helix Research Institute

Astellas Pharma Gmbh

Yamanouchi Pharmaceutical Company Ltd.

Acceleron Pharma Inc.

Takao Isogai

Ai Wakamatsu

Tetsuo Nishikawa

Toshio Ota

Tomoyasu Sugiyama

Keiichi Nagai

Jun-Ichi Yamamoto

Kaoru Otsuka

Shizuko Ishii

Tetsuji Otsuki

Yuri Hio

Hitoshi Kojo

Yasuhiko Masuho

Koji Hayashi

Hiroyuki Sato

Kenji Nagahari

Ryotaro Irie

Naohiko Seki

Yuuko Isono

Motoyuki Otsuka

Tsutomu Yoshikawa

Ichiro Tamechika

Morita Iwami

Shin-Ichi Funahashi

Shoji Miyata

Ichiro Aramori

Masao Fukagawa

Kenji Sobue

Yuri Kawai

Masaru Yoshida

Jun Takasaki

Susumu Satoh

Masazumi Kamohara

Hiroki Ono

Mitsuyuki Matsumoto

Tetsu Saito

Hiroyuki Arakawa

Mayako Yamazaki

Masahiko Morita

Junichi Yamamoto

Tohru Sugimoto

It is an object of the present invention to provide diagnostic reagents, pharmaceuticals and the like for particular diseases, and providing means that are useful in developing such reagents, pharmaceuticals and the like. The present invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as cancer-specific biomarkers; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for a cancer-specific biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of a cancer-specific biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for a cancer-specific biomarker, and a reagent comprising them and the like.

Biomarker specific for cancer

The invention provides a polypeptide and a specific partial peptide thereof, as well as a polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.

Biomarker specific to brain/nerve or specific to neuronal differentiation

A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No. 2000-118776) were retrieved, and thus, a novel gene 'C-NT2RP3001495' was obtained. The protein encoded by this gene has two WW domains that participate in protein interactions in the N-terminal domain. Evidence suggests that this protein binds to other proteins, and thus regulates the intracellular signal transduction, gene expression, and so on, thereby participating in the maintenance of the differentiation of smooth muscle cells. This protein and compounds regulating the expression thereof are markedly useful in developing drugs for various diseases associated with abnormality in the maintenance of smooth muscle cell differentiation.

Antibody directed to protein involved in maintaining differentiation of smooth muscle cells

Novel full-length cDNAs are provided. cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

Heart20049410 full-length cDNA and polypeptides

Genes associated with the maintenance of differentiation of smooth muscle cells

A cDNA encoding a novel LTCreceptor has been isolated. Provision of the novel protein, an LTCreceptor, enabled binding experiments using the LTC. By screening for compounds that modulate LTCreceptor activity based on these binding experiments, development of drugs targeting the LTCreceptor becomes possible.

Peptide leukotriene receptor

Novel full-length cDNAs are provided. 2443 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

Full-length cDNA

Human cDNA encoding a secretory or membrane protein useful as a candidate for developing medicine or as a target molecule for developing medicine. The expression level of the polynucleotide of the present invention increased in NT2 cells after retinoic acid-treatment. Accordingly, this cDNA is associated neurological disease.

Secretory protein or membrane protein

The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; and therapeutic agents for treating or preventing Alzheimer's diseases comprising a compound that regulates the activity of a protein suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein.

Amyloid-&#x3b2; protein aggregation-regulating factors

Novel full-length cDNAs are provided. 1639 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

Amyloid &#x3b2; protein agglutination-controlling factor

Novel full-length cDNAs are provided. 1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

D-amino acid oxidase (DAO) originated from Fusarium solani M-0718, a DNA compound encoding the oxidase, expression vectors containing said DNA compound are provided. Esherichia coli transformants capable of producing recombinant DAO in high level are also provided.

D-amino acid oxidase of F. solani and methods for its recombinant

Growing community of inventors

Ibaraki, Japan

Takao Isogai